-- 
Israeli Stocks: Camtek, Given Imaging, Israel Chemicals, Nova

-- B y   R o n i t   G o o d m a n
-- 
2011-02-16T15:45:23Z

-- http://www.bloomberg.com/news/2011-02-16/israeli-stocks-camtek-given-imaging-israel-chemicals-nova.html
  Israel ’s TA-25 Index increased to
the highest level since Jan. 23, gaining 1.5 percent to 1,334.55
at the 4:30 p.m. close in Tel Aviv. Investors traded about 1.96
billion shekels ($543 million) in shares and convertible
securities.  The following stocks rose or fell today. Symbols are in
parentheses.  Camtek Ltd. (CAMT IT) climbed to the highest level since
July 2007, advancing 3.9 percent to 15.30 shekels. The maker of
optical-inspection systems received an order for multiple wafer
inspection systems from “one of the world’s largest
manufacturers” of CMOS Image Sensor.    Given Imaging Ltd . (GIVN IT) fell for the second time this
week, retreating 1.4 percent to 67.20 shekels. The maker of a
pill-sized camera for diagnosing digestive ailments said fourth-
quarter net income dropped to $3.2 million from $5.4 million in
the year-earlier period. The company expects 2011 revenue of
between $165 million and $173 million.    Israel Chemicals Ltd . (ICL IT) increased to the highest
since Jan. 19, adding 1.3 percent to 63.40 shekels. The
Histadrut labor federation said a strike at the Dead Sea Works
Ltd. unit of the company that extracts minerals from the Dead
Sea to make fertilizer has ended.    Nova Measuring Instruments Ltd . (NVMI IT) gained 1.9
percent to 40.13 shekels, the highest since the shares were
listed in Tel Aviv in June 2002. The maker of measuring
instruments for the semiconductor industry has soared 11 percent
in the past two days. Nova’s price estimate was raised to $15
per share from $11 at Needham & Co. Yesterday, Nova posted an
increase in fourth-quarter earnings and issued a first-quarter
revenue outlook that topped analysts’ estimates.  To contact the reporter on this story:
Ronit Goodman in  Tel Aviv  at 
 rgoodman9@bloomberg.net   To contact the editor responsible for this story:
Claudia Maedler at 
 cmaedler@bloomberg.net  